Home › Trials › NCT06994169
Clinical trial Recruiting at 30 sites Observational Ages 18 and up

Real-world outcomes with glofitamab for large B-cell lymphoma

Official title: Glofitamab in Real Life

Run by The Lymphoma Academic Research Organisation · NCT06994169 · Data updated 2026-11-12

This project looks at how well glofitamab works and how safe it is for adults in France with relapsed or refractory large B‑cell lymphoma who were treated through the expanded access program.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment250 (estimated)
SponsorThe Lymphoma Academic Research Organisation
Academic / other
Drugs / interventionsGlofitamab, Obinutuzumab, CAR-T
Locations30 sites (Argenteuil and 29 other locations)
StatusRecruiting
StartedDecember 1, 2025
Main results expectedMarch 27, 2026
Study endsDecember 30, 2026
Registry record updatedJune 3, 2026
Trial IDNCT06994169 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adult patients enrolled in the French glofitamab expanded-access program before November 1, 2024 who received obinutuzumab pretreatment and at least one glofitamab infusion and who did not oppose data collection.

Probably not a fit

Patients not treated in the French EAP, pediatric patients, or those who did not receive obinutuzumab pretreatment or any glofitamab infusion are unlikely to be represented and therefore may not benefit from the study findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational analysis of over 300 adults treated with glofitamab in the French expanded-access program, with an expected median follow-up of more than nine months. The project will summarize real-world efficacy and safety outcomes across participating centers. Special attention is given to patients previously treated with CAR‑T therapy to confirm reported complete response rates and to explore optimal timing of glofitamab initiation. Included patients received obinutuzumab pretreatment and at least one glofitamab infusion and did not object to use of their data.

Why it matters

Potential benefit: If successful, the findings could help clinicians better predict which patients benefit from glofitamab and inform optimal timing of treatment in relapsed/refractory large B‑cell lymphoma.

How similar studies have gone: Previous clinical trials and expanded-access reports have shown promising response rates for glofitamab, including reported CRR around 35–39% in CAR‑T‑exposed patients, but large real‑world cohorts are still limited.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024
* patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab
* adult patient
* patient who is informed of the study and who did not oppose to their data collection

Exclusion Criteria:

* none

Where it's running

  • CH Victor Dupouy
    Argenteuil, France     Recruiting
  • CH d'Avignon - Hôpital Henri Dufaut
    Avignon, France     Recruiting
  • CH de la Côte Basque
    Bayonne, France     Recruiting
  • CHRU Besançon - Hôpital Minjoz
    Besançon, France     Recruiting
  • Hopital D'Instruction Des Armees Percy
    Clamart, France     Recruiting
  • Hopital Henri Mondor
    Créteil, France     Recruiting
Show 24 more locations
  • CHU de Dijon - Hôpital le Bocage
    Dijon, France     Recruiting
  • CH de Dunkerque
    Dunkirk, France     Recruiting
  • CHU de Grenoble - Hôpital Albert Michallon
    La Tronche, France     Recruiting
  • Hôpital de Libourne
    Libourne, France     Recruiting
  • CHRU de LILLE - Claude Huriez
    Lille, France     Recruiting
  • Hopital Saint Vincent-de-Paul
    Lille, France     Recruiting
  • Centre Léon Bérard
    Lyon, France     Recruiting
  • INSTITUT PAOLI CALMETTES - Service Hématologie
    Marseille, France     Recruiting
  • Clinique du Pont de Chaume
    Montauban, France     Recruiting
  • CH de Mulhouse Sud Alsace
    Mulhouse, France     Recruiting
  • CHR d'Orléans
    Orléans, France     Recruiting
  • Hopital Saint-Louis
    Paris, France     Recruiting
  • Chu de Bordeaux - Hopital Haut-Leveque
    Pessac, France     Recruiting
  • CHU Lyon Sud
    Pierre-Bénite, France     Recruiting
  • CHU de Poitiers - Hôpital de La Milétrie
    Poitiers, France     Recruiting
  • CH de Quimper Cornouaille
    Quimper, France     Recruiting
  • CHU de Rennes - Hôpital de Pontchaillou
    Rennes, France     Recruiting
  • Institut Curie - Site Saint-Cloud
    Saint-Cloud, France     Recruiting
  • CHU de Strasbourg
    Strasbourg, France     Recruiting
  • Institut Universitaire du Cancer de Toulouse - Oncopole
    Toulouse, France     Recruiting
  • Chu Bretonneau
    Tours, France     Recruiting
  • CHRU de Nancy - Hôpital de Brabois
    Vandœuvre-lès-Nancy, France     Recruiting
  • Ch de Bretagne Atlantique
    Vannes, France     Recruiting
  • Gustave Roussy Cancer Campus Grand Paris
    Villejuif, France     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Large B-cell Lymphoma 61Glofitamab 36The Lymphoma Academic Research Organisation 8
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.